Pneumococcal 23-valent vaccine - Sinovac Biotech

Drug Profile

Pneumococcal 23-valent vaccine - Sinovac Biotech

Alternative Names: 23-valent pneumococcal polysaccharide vaccine - Sinovac Biotech; 23-valent PPV - Sinovac

Latest Information Update: 25 Jun 2015

Price : $50

At a glance

  • Originator Sinovac Biotech
  • Class Pneumococcal vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Pneumococcal infections

Most Recent Events

  • 01 Apr 2015 Phase-III clinical trials in Pneumococcal infections (In children, In adults, In the elderly, Prevention) in China (IM) (NCT02451969)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top